Watson Pharmaceuticals, Inc. (NYSE: WPI) announced that the results of an open-label extension of two Phase 3 studies, published in the December issue of the peer-reviewed journal Urology, demonstrate long-term safety and tolerability of RAPAFLO® (silodosin) for up to 52 weeks of treatment. RAPAFLO® is an effective and uniquely selective alpha blocker for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH), the number one reason patients visit urologists…




New Published Data Demonstrate Long-Term Safety, Efficacy And Tolerability Of Watson’s RAPAFLO(R) (silodosin) For Benign Prostatic Hyperplasia (BPH)



Rox PharmacySponsored by RoxPharmacy.com - Online Pharmacy, an pharmacy online supplies more than 500 quality generic products, free prescription, worldwide shipping.
xanax

Online Canadian Pharmacy canada pharmacy
Share and Enjoy:
  • Digg
  • del.icio.us
  • Facebook
  • Google Bookmarks
  • LinkedIn
  • Live
  • StumbleUpon
  • Yahoo! Buzz
  • Slashdot
  • Technorati
  • MSN Reporter

Related posts:

  1. Urodynamic Effects Of Silodosin, A New Alpha(1A)-Adrenoceptor Selective Antagonist, For The Treatment Of Benign Prostatic Hyperplasia
  2. Urodynamic Effects Of Silodosin, A New Alpha(1A)-Adrenoceptor Selective Antagonist, For The Treatment Of Benign Prostatic Hyperplasia
  3. Effects Of Once-Daily Tadalafil On Erectile Function In Men With Erectile Dysfunction And Signs And Symptoms Of Benign Prostatic Hyperplasia